Assuming the results are positive, I actually think the market's demonstrated lack of understanding about RAC may have a positive impact on the share price. The market doesn't put enough weight on our current preclinicals as we've seen, because they aren't able to contextualise them against Bisantrene's historical in-human results and RAC's contemporary strategy, but I think with this announcement it's quite possible they will see the "in human" aspect of the announcement and give the share price a boost as a result, even though this specific trial isn't the most critical of our in-human trials.
Assuming the results are positive, I actually think the market's...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |